Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Down 1.8%

Santen Pharmaceutical Co. (OTCMKTS:SNPHY) shares fell 1.8% during mid-day trading on Monday . The stock traded as low as $19.47 and last traded at $19.51, 5,555 shares traded hands during mid-day trading. An increase of 15% from the average session volume of 4,817 shares. The stock had previously closed at $19.87.

Separately, Jefferies Financial Group began coverage on Santen Pharmaceutical in a research note on Monday, December 9th. They issued a “hold” rating for the company.

About Santen Pharmaceutical (OTCMKTS:SNPHY)

Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117.

Recommended Story: What member countries make up the G-20?

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.